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Summary Symptomatic brain metastases are found in about 40% of patients with small cell lung cancer.
Cranial irradiation is the first line treatment for this form of metastatic disease. Frequently brain metastases
recur after this treatment or develop after prophylactic cranial irradiation. For these patients no effective
antitumour therapy is available. In this study the efficacy of high dose etoposide 1.5 gm-2 was evaluated. In
10 (43%) out of 23 evaluable patients a response was seen. Toxicity was severe with five aplasia-related
deaths. For palliative purposes this regimen is too toxic in heavily pretreated patients.
Brain metastases become symptomatic in about 40% of
patients with small cell lung cancer (SCLC). For such
patients cranial radiotherapy is the only available treatment,
resulting in complete resolution of the often serious neuro-
logical symptoms in 35-65% of the treated patients (Cox et
al., 1980; Baglan & Marks, 1980). However, up to 25% of
the patients die before the cranial radiotherapy has been
initiated or completed (Nugent et al., 1979). Median survival
after the end of cranial radiotherapy is only 3-4 months
(Cox et al., 1980; Nugent et al., 1979), and tumour
progression outside the central nervous system (CNS) is
often the cause of'death (Nugent et al., 1979). There is no
effective antitumour therapy for patients in whom brain
metastases develop after either therapeutic or so-called
prophylactic cranial irradiation (PCI). Favourable responses
of CNS metastases from SCLC were found after high dose
cyclophosphamide and etoposide with autologous bone
marrow transplantation (Postmus et al., 1984a) and in a
phase I study of high dose etoposide (HDE) (Postmus et al.,
1984b). Based on these results the EORTC Lung Cancer
Cooperative Group decided to perform a phase II study of
HDE in patients with brain metastases from SCLC.
Preliminary results, particularly of toxicity of this study,
have already been published (Postmus et al., 1987).
Materials and methods
Patients
All patients entering protocol 08841 had histologically or
cytologically proven SCLC. Eligibility criteria for entry on
the study included: age <75 years, ECOG performance
<3, normal bilirubin level (<25yumoll-1) normal serum
creatinine (< 125umo1-1); WBC 3.0 x 1091-1,
platelets > 100 x 109 1 -1.
Brain metastases were documented and measured by
contrast enhanced computer tomography (CT). If previous
therapeutic or prophylactic cranial radiotherapy had been
given this had been completed more than 6 weeks before
entrance into the study. Moreover, in these patients brain
metastases should be progressive, based on clinical signs
and/or brain CT.
Therapy
Etoposide (VP 16-213) was dissolved in normal saline,
maximum concentration 0.8 mgml- 1. The total dose per
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cycle was 1.5gm2, given by 6 one-hour infusions with 12
hours' interval on three consecutive days with four weeks'
interval. The therapy was continued until progression or at
most four courses had been completed.
Dose reductions for any reason were not allowed. If
symptoms due to oedema around the metastases were
disabling dexamethasone was given orally at a dose of 4mg
six-hourly. Within three weeks this had to be tailed off to
zero unless symptoms due to brain metastases recurred.
Platelet transfusions were given when platelet numbers were
below 10x 1091-. In case of persistent high fever, broad
spectrum antibiotics were administered.
Response
Response was evaluated after each course by neurological
investigation and after one and four courses by repeat brain
CT.
A complete response (CR) was defined as a complete
disappearance of the tumour lesions on CT and a partial
remission (PR) as a reduction of 50% or more of the
product of the perpendicular diameters of an enhancing
lesion or a similar reduction in the sum of the products of
the perpendicular diameters of enhancing lesions on CT,
without an increase in size of any of the lesions or
development of new lesions. Stable disease (SD) was defined
as an increase of less than 25% or decrease of less than 50%
of the enhancing lesion(s) without development of new
lesions and no worsening of neurological symptoms.
Progressive disease (PD) was defined as appearance of a new
lesion or an increase of more than 25% of a lesion and/or
worsening of neurological symptoms attributed to the
metastases.
Toxic death (TD) is death due to toxicity of the treatment
and early death (ED) is death due to tumour progression
before the first control CT of the brain. Response duration
and survival were measured from the start of HDE.
Toxicity
Toxicity (WHO-grading) was scored after two and three
weeks from the first day of each course.
Results
Patients
Twenty-eight patients were entered: two female, 26 male,
mean age 58 years (range 38-71), ECOGPS 0-1 thirteen, 2-
3 fifteen. Twenty-seven patients were heavily pretreated with
combination chemotherapy, in 25 etoposide had been given
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at standard dose and in eight patients the primary tumour
had been irradiated.
Sixteen patients had received previous cranial irradiation,
nine as PCI and seven for (a) symptomatic brain metastases.
Eighteen patients were given corticosteroids to improve
neurological symptomatology at the start of treatment. The
median time between the moment SCLC was diagnosed and
the brain metastases was 11.5 months (range 1-43). The
median period between the last chemotherapy course and the
start of high dose etoposide was 3 months (range 0-24). Six
patients also had tumour progression outside the CNS.
Twenty-three patients were evaluable for response and
toxicity, one patient committed suicide shortly after the start
of therapy and four patients received too low a dose (0.8-
1.0 gm-2), and were therefore not evaluable for efficacy and
toxicity.
Response
Twenty-three patients were evaluable for response (Table I).
Five patients died during aplasia related septicaemia. Before
the second evaluation in six patients therapy was stopped.
One patient refused after one course because of too severe
subjective toxicity, two after two courses and one after three
courses. In all these patients there were no signs of tumour
progression. In one patient PD in the brain was seen after
two courses and in one patient liver metastases were
progressive. Only six patients received four courses. The best
response scored in all patients regardless of length of therapy
was 3 CR, 7 PR, 2 SD. The response rate was 43%. In all
patients responding to the chemotherapy it was possible to
stop the corticosteroids. Median response duration was 14
weeks (range 8-40). The median survival from the start of
HDE in responding patients was 8 months (range 3-24+).
The median survival of non-responders was 1 month (range
0-18+). Of the 10 responding patients, seven had previously
received brain irradiation (Table II).
Toxicity
Forty-eight courses were given. In 40% grade 3-4 leukocyto-
penia and in 44% grade 3-4 thrombocytopenia were seen.
During 29% of the courses fever, probably due to infection,
was seen. In 4% of the courses platelet transfusions were
necessary. Five patients died during aplasia-related septic-
aemia. Extra-medullary toxicity consisted of alopecia in all
patients; mucositis of the oropharynx was mild, grade 1 in
5% of courses, grade 2 in 5% of the courses and grade 3 in
2% of the courses.
Discussion
In this study a 43% response rate of brain metastases from
SCLC was found. This response rate confirms the result of
Kleisbauer et al. (1988) in a small group of SCLC patients
with brain metastases and confirms the impression gained
from our phase I trials.
The efficiency of cytotoxic drugs in preventing or treating
CNS metastases has not been sufficiently studied in SCLC.
In a number of randomised studies drugs that cross the
Table I Response in 23 evaluable patients
After one After four Best
course courses response





Table II Response and brain irradiation
Previous brain
irradiation Yes No
Number of patients 15 8
Best response CR 2 1
PR 5 2
SD 3 -
blood-brain barrier (BBB), i.e. procarbazine, nitrosureas and
high dose methotrexate, have been added to combination
chemotherapy regimens to prevent CNS-relapse. However,
this approach resulted in the same frequency of CNS relapse
as was seen after treatment with other cytotoxic drugs (Bunn
et al., 1978; Neystrom et al., 1983). Adding etoposide at
standard dose to combination regimens did not improve the
CNS relapse frequency (Cohen et al., 1979).
Recently in two small groups of patients with newly
diagnosed SCLC and brain metastases, responses after
standard dose combination chemotherapy have been
reported (Kirstjansen & Hansen, 1988; Twelves et al., 1987).
These observations are remarkable because at standard dose
the penetration of etoposide into the cerebral spinal fluid
(CSF) is minimal (Creaven, 1982), whereas HDE resulted in
much higher levels in the CSF (Postmus et al., 1984c).
It is unclear whether these CSF levels really reflect the
CNS tissue levels. Regarding the lipophilic character of
etoposide, the tissue levels might even be higher than CSF
levels. The role of the BBB in patients with symptomatic
metastases might be less important than in patients without
metastases. The destructive effect of brain irradiation,
resulting in enhanced permeability of the BBB, is probably
important (Caveness, 1980). However, the number of
patients in this study is small and no striking differences are
present.
From the results presented in the study it is also not clear
how high the dose needs to be, although incidentally no
responses were found in the four patients who received a
lower dose than scheduled. The high number of toxic deaths
and the overall toxicity in this study is a major disadvantage
of HDE and we consider it too toxic, especially in heavily
pretreated patients, for palliative therapy. Further studies are
necessary to find a less toxic therapy for this otherwise
resistant form of metastatic disease. Possible alternatives are
lower doses of etoposide (Twelves et al., 1987; Creaven,
1982) or standard doses of the more lipophilic, related
compound teniposide (Giaccone et al., 1988, Haaxma-Reiche
et al., 1989). The latter is currently being tested in EORTC
protocol 08873.
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